Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.7720
-0.0117 (-1.49%)
At close: Aug 13, 2025, 4:00 PM
0.7870
+0.0150 (1.94%)
After-hours: Aug 13, 2025, 5:24 PM EDT
Sutro Biopharma Revenue
Sutro Biopharma had revenue of $63.75M in the quarter ending June 30, 2025, with 147.98% growth. This brings the company's revenue in the last twelve months to $104.47M, down -38.31% year-over-year. In the year 2024, Sutro Biopharma had annual revenue of $62.04M, down -59.64%.
Revenue (ttm)
$104.47M
Revenue Growth
-38.31%
P/S Ratio
0.62
Revenue / Employee
$337,010
Employees
310
Market Cap
65.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
STRO News
- 6 days ago - Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Sutro Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 - GlobeNewsWire
- 5 months ago - Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - GlobeNewsWire
- 5 months ago - Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline - Benzinga
- 5 months ago - Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline - GlobeNewsWire